Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
54 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
AVEO Pharmaceuticals, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'AVEO Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the AVEO Pharmaceuticals, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of AVEO Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of AVEO Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of AVEO Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the AVEO Pharmaceuticals, Inc.'s pipeline products Reasons to buy - Evaluate AVEO Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of AVEO Pharmaceuticals, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the AVEO Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of AVEO Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of AVEO Pharmaceuticals, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of AVEO Pharmaceuticals, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 AVEO Pharmaceuticals, Inc. Snapshot 5 AVEO Pharmaceuticals, Inc. Overview 5 Key Information 5 Key Facts 5 AVEO Pharmaceuticals, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 AVEO Pharmaceuticals, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Pipeline Products - Out-Licensed Products 13 Out-Licensed Products/Combination Treatment Modalities 14 AVEO Pharmaceuticals, Inc. - Pipeline Products Glance 15 AVEO Pharmaceuticals, Inc. - Late Stage Pipeline Products 15 Filing rejected/Withdrawn Products/Combination Treatment Modalities 15 AVEO Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 16 Phase II Products/Combination Treatment Modalities 16 Phase I Products/Combination Treatment Modalities 17 AVEO Pharmaceuticals, Inc. - Early Stage Pipeline Products 18 Preclinical Products/Combination Treatment Modalities 18 Discovery Products/Combination Treatment Modalities 19 AVEO Pharmaceuticals, Inc. - Drug Profiles 20 tivozanib 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 ficlatuzumab 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 AV-203 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 AV-232 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 GP-369 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Anti-Notch2 Monoclonal Antibody 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Anti-Notch3 Monoclonal Antibody 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Anti-Notch4 Monoclonal Antibody 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 AV-380 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 FGFR1 Inhibitory Monoclonal Antibody 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 FGFR4 Inhibitory Monoclonal Antibody 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 AVEO Pharmaceuticals, Inc. - Pipeline Analysis 34 AVEO Pharmaceuticals, Inc. - Pipeline Products by Target 34 AVEO Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 36 AVEO Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 37 AVEO Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 38 AVEO Pharmaceuticals, Inc. - Recent Pipeline Updates 40 AVEO Pharmaceuticals, Inc. - Dormant Projects 47 AVEO Pharmaceuticals, Inc. - Discontinued Pipeline Products 48 Discontinued Pipeline Product Profiles 48 AV-412 48 tivozanib 48 AVEO Pharmaceuticals, Inc. - Company Statement 49 AVEO Pharmaceuticals, Inc. - Locations And Subsidiaries 52 Head Office 52 Appendix 53 Methodology 53 Coverage 53 Secondary Research 53 Primary Research 53 Expert Panel Validation 53 Contact Us 54 Disclaimer 54
List of Tables AVEO Pharmaceuticals, Inc., Key Information 5 AVEO Pharmaceuticals, Inc., Key Facts 5 AVEO Pharmaceuticals, Inc. - Pipeline by Indication, 2014 8 AVEO Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 9 AVEO Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 10 AVEO Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2014 11 AVEO Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 12 AVEO Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2014 13 AVEO Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 14 AVEO Pharmaceuticals, Inc. - Filing rejected/Withdrawn, 2014 15 AVEO Pharmaceuticals, Inc. - Phase II, 2014 16 AVEO Pharmaceuticals, Inc. - Phase I, 2014 17 AVEO Pharmaceuticals, Inc. - Preclinical, 2014 18 AVEO Pharmaceuticals, Inc. - Discovery, 2014 19 AVEO Pharmaceuticals, Inc. - Pipeline by Target, 2014 35 AVEO Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 36 AVEO Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 37 AVEO Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 39 AVEO Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 40 AVEO Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 47 AVEO Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014 48
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
